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Abstract
Visfatin, also known as extracellular pre–B-cell colony–enhancing factor (PBEF) and nicotinamide phosphoribosyltransferase
(Nampt), is an adipocytokine whose circulating levels are enhanced in metabolic disorders, such as type 2 diabetes mellitus and
obesity. Circulating visfatin levels have been positively associated with vascular damage and endothelial dysfunction. Here, we
investigated the ability of visfatin to directly impair vascular reactivity in mesenteric microvessels from both male Sprague-
Dawley rats and patients undergoing non-urgent, non-septic abdominal surgery. The pre-incubation of rat microvessels with
visfatin (50 and 100 ng/mL) did not modify the contractile response to noradrenaline (1 pmol/L to 30 mmol/L), as determined
using a small vessel myograph. However, visfatin (10 to 100 ng/mL) concentration-dependently impaired the relaxation to
acetylcholine (ACh; 100 pmol/L to 3 mmol/L), without interfering with the endothelium-independent relaxation to sodium
nitroprusside (1 nmol/L to 3 mmol/L). In both cultured human umbilical vein endothelial cells and rat microvascular
preparations, visfatin (50 ng/mL) stimulated nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, as
determined by lucigenin-derived chemiluminiscence. The relaxation to ACh impaired by visfatin was restored by the NADPH
oxidase inhibitor apocynin (10 mmol/L). Additionally, the Nampt inhibitor APO866 (10 mmol/L to 10 mmol/L), but not an insulin
receptor-blocking antibody, also prevented the stimulation of NADPH oxidase and the relaxation impairment elicited by visfatin.
Accordingly, the product of Nampt activity nicotinamide mononucleotide (100 nmol/L to 1 mmol/L) stimulated endothelial
NADPH oxidase activity and concentration-dependently impaired ACh-induced vasorelaxation. In human mesenteric
microvessels pre-contracted with 35 mmol/L potassium chloride, the endothelium-dependent vasodilation to bradykinin
(1 nmol/L to 3 mmol/L) was equally impaired by visfatin and restored upon co-incubation with APO866. In conclusion, visfatin
impairs endothelium-dependent relaxation through a mechanism involving NADPH oxidase stimulation and relying on Nampt
enzymatic activity, and therefore arises as a potential new player in the development of endothelial dysfunction.
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Introduction
In 2005, visfatin was identified as a novel adipocytokine
preferently released by visceral fat and exhibiting insulin-mimetic
properties [1]. This latter statement, however, was retracted due to
reproducibility concerns on the hypoglycemic properties of visfatin
[2]. Visfatin has been found identical to the cytokine pre-B colony-
enhancing factor-1 (PBEF) [3], and to the extracellular form of
nicotinamide phosphoribosyltransferase (Nampt), the rate-limiting
enzyme in the NAD salvage synthetic pathway biosynthesis that
transforms nicotinamide into nicotinamide monoucleotide (NMN)
[4].
Recently, several observations have suggested a direct associa-
tion between plasma visfatin levels and endothelial dysfunction.
Thus, in clinical conditions, such as type 2 diabetes mellitus and
chronic kidney disease, a positive correlation has been reported
between plasma visfatin levels and those of several markers of
endothelial injury and systemic inflammation, including soluble
vascular cell adhesion molecule-1, intercellular cell adhesion
molecule, CD146, monocyte chemoattractant protein, C-reactive
protein, or interleukin-6 [5–8]. Furthermore, a negative associa-
tion has been found between circulating visfatin levels and brachial
artery flow-mediated dilation (FMD), used as a non-invasive
measurement of endothelial function in humans [7,9,10]. Indeed,
in patients undergoing renal transplantation, visfatin has been
identified as a strong predictor of FMD and the reduction of
plasma visfatin levels following transplantation is accompanied by
the normalization of the endothelial function [11].
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The findings presented above allow us for proposing that,
besides representing a novel biomarker of endothelial dysfunction,
visfatin might also be an active player in directly impairing
vascular reactivity. However, little is known at present about the
capacity of visfatin to directly influence the vascular tone. To
address this question, we used mesenteric arteries from both rat
and human origin to explore the influence of visfatin on both
contractile and vasorelaxant microvascular responses, with special
attention to the role played by two enzymes, namely nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase, as a superox-
ide anions-generating enzyme closely associated to endothelial
dysfunction [12,13], and Nampt.
Materials and Methods
Ethics statement
The investigation conforms to the principles outlined in the
Declaration of Helsinki and to Spanish legal dispositions.
Experiments with human endothelial cells were reviewed and
approved by the ethics committee of Universidad Auto´noma de
Madrid and Hospital Universitario de Getafe. Experiments with
human omentum microvessels were reviewed and approved by the
ethics committee of Universidad Auto´noma de Madrid and
Hospital Universitario de La Princesa. In every case, written
informed consent was obtained from the donor. The investigation
with animals conforms to national guidelines and was approved by
the ethics committee of Universidad Auto´noma de Madrid (CEI
27–660).
Materials
Culture plasticware was from TPP (Tragadingen, Switzerland).
Culture medium M199, fetal calf serum (FCS) and trypsin-EDTA
were from Biological Industries (Beit-Haemek, Israel). Human
recombinant visfatin, with an endotoxin level below 0.1 ng per mg,
was purchased from Peprotech (London, UK). The blocking
mouse monoclonal antibody (Ab-3, clone 47–9) against the insulin
receptor (a subunit) was purchased from Labvision (Fremont, CA,
USA). The Nampt inhibitor APO866 was kindly donated by
Topotarget (Lausanne, Switzerland). Endothelial cell growth
supplement (ECGS), noradrenaline (NA), potassium chloride
(KCl), acetylcholine (ACh), bradykinin (BK), sodium nitroprusside
(SNP), superoxide dismutase (SOD), nicotinamide mononucleo-
tide (NMN), apocynin and, unless otherwise stated, all other
reagents were purchased from Sigma Chemical Co. (St. Louis,
MO, USA).
Vascular reactivity
Vascular reactivity was studied in both rat and human
mesenteric arteries using a small vessel myograph to measure
isometric tension, as previously described [14,15].
On one side, 3 month-old male Sprague-Dawley rats (250 g)
were used for animal studies. Prior to the experiments, the animals
were briefly exposed to carbon dioxide in a chamber until they fell
unconscious and were then immediately killed by cervical
dislocation. The third branch mesenteric arteries (mean internal
diameter 309.062.5 mm) were dissected, cleaned free of fat and
connective tissue, mounted as ring preparations and first
contracted with 125 mmol/L KCl followed by washout to
determine viability. A first set of experiments was designed to
assess the influence of visfatin on NA-induced vasoconstriction.
Thus, rat microvascular segments were pre-incubated or not for
20–30 min with visfatin (50 and 100 ng/mL) and then contracted
with increasing concentrations of NA (1 pmol/L to 30 mmol/L). A
second set of experiments aimed to address the influence of visfatin
on endothelium-dependent vasorelaxation. Thus, the microvessels
were pre-incubated or not for 20–30 min with visfatin (10 to
100 ng/mL), stimulated with NA (1 mmol/L) and, once the
contraction became stable, the vasorelaxant responses to the
endothelium-dependent vasodilator ACh (100 pmol/L to 3 mmol/
L) were tested by the addition of cumulative concentrations of the
drug. The relaxations to SNP (1 nmol/L to 3 mmol/L), as an
endothelium-independent vasodilator, were also studied. In some
experiments and prior to the contraction with NA, the mesenteric
segments were pre-incubated with other compounds, such as
NMN, APO866, an insulin receptor blocking antibody, apocynin,
L-NAME, indomethacin or SOD, at the indicated concentrations.
The studies in human microvessels were performed using
mesenteric arteries obtained from omentum samples from 4 female
patients (age, 4369 yr, range 24–62 yr) undergoing non-urgent, non-
septic abdominal surgery at Hospital Universitario de la Princesa, as
previously described [15]. After viability confirmation using
125 mmol/L KCl and washout, the human mesenteric segments
(mean internal diameter 245.062.2 mm) were pre-contracted with
35 mmol/L KCl and subsequently exposed to increasing concentra-
tions of the endothelial-dependent vasodilator BK (1 nmol/L to
3 mmol/L). Some segments were pre-incubated for 20–30 min with
visfatin, APO866 or both drugs together at the indicated concentra-
tions before the contraction with 35 mmol/L KCl.
Endothelial cell isolation and culture
Human umbilical vein endothelial cells (HUVEC) were
enzymatically isolated with collagenase and cultured in M199
medium supplemented with 10% FCS, 25 mg/mL ECGS,
100 mg/mL heparin and antibiotics, as previously described
[16]. For experiments, HUVEC at passages 1–5 were used.
NADPH oxidase activity assay
The activity of NADPH oxidase was measured in both HUVEC
and rat microvascular preparations by lucigenin-derived chemilu-
miniscence. Briefly, samples were treated with the different
compounds to be tested for 20–30 min. At the end of the
treatment, HUVEC were washed in ice-cold phosphate-buffered
saline, scraped and centrifuged at 13,000 rpm for 1 minute at 4uC.
Figure 1. Visfatin does not modify NA-induced contraction in
rat mesenteric microvessels. After pre-incubation with visfatin (50
and 100 ng/mL), the microvessels were contracted with increasing
concentrations of NA (1 nmol/L to 30 mmol/L). Results are expressed as
percentage of a previous contraction elicited by 125 mmol/L potassium
chloride (KCl). Results are expressed as mean 6 SEM of 17 segments
obtained from 4 animals.
doi:10.1371/journal.pone.0027299.g001
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The resulting cell pellet, as well as the microvascular preparations,
was homogenized in lysis buffer (pH 7.0) containing 50 mmol/L
KH2PO4, 1 mmol/L EGTA and 150 mmol/L sucrose at 4uC.
For every sample, the protein content was determined by the
bicinchoninic acid method. Cellular or microvascular extracts
were then incubated in phosphate-buffered saline containing
5 mmol/L lucigenin and 100 mmol/L NADPH and luminiscence
was then measured every 10 seconds for 5 minutes in a tube
luminometer (Optocomp, MGM Instruments, Hamden, CT,
USA). The enzymatic activity was expressed as relative light units
(RLU)/mg of protein/min.
Statistical analysis
Results are expressed as mean6SEM. Statistical analysis was
performed using Student’s t test for data points and ANOVA for
curves, with the level of significance chosen at P,0.05.
Results
Visfatin does not modify NA-induced contraction in rat
mesenteric microvessels
In a first set of experiments, the ability of visfatin to modify
microvascular contractions was explored. Thus, rat mesenteric
arteries, were concentration-dependently contracted with cumu-
lative concentrations of NA (1 nmol/L to 30 mmol/L; Figure 1).
The pre-incubation of the microvessels with visfatin (50 and
100 ng/mL) did not modify the contractile responses to NA
(Figure 1).
Visfatin impairs the endothelium-dependent vasodilation
to ACh in rat mesenteric microvessels
Despite its lack of effect on NA-induced contraction, visfatin (10
to 100 ng/mL) concentration-dependently impaired the relaxation
Figure 2. Visfatin impairs the vasodilation induced by ACh in rat mesenteric microvessels. (A) After pre-incubation with visfatin (10 to
100 ng/mL), the microvessels were contracted with 1 mmol/L NA and then exposed to cumulative concentrations of the endothelium-dependent
vasodilator ACh (100 pmol/L to 3 mmol/L). Results are expressed as mean 6 SEM of 35 segments obtained from 5 animals. *P,0.05 vs control curve.
(B) Correlation between the concentrations of visfatin used for pre-incubation and the pD2 values for ACh. (C) The microvessels were pre-incubated
with visfatin (100 ng/mL), the endothelial oxide synthase inhibitor L-NAME (100 mmol/L), the cyclooxygenase inhibitor indomethacin (Indo; 10 mmol/
L) or different combinations of these compounds, and then contracted with 1 mmol/L NA and exposed to cumulative concentrations of ACh
(100 pmol/L to 3 mmol/L). Results are expressed as mean 6 SEM of 56 segments obtained from 12 animals. *P,0.05 vs control curve. (D) After pre-
incubation or not with visfatin (50 ng/mL) and contraction with 1 mmol/L NA, the microvessels were exposed to the endothelium-independent
vasorelaxant sodium nitroprusside (SNP; 1 nmol/L to 3 mmol/L). Results are expressed as mean 6 SEM of 19 segments obtained from 4 animals.
doi:10.1371/journal.pone.0027299.g002
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elicited by cumulative concentrations of ACh (100 pmol/L to
3 mmol/L) in rat microvessels pre-contracted with 1 mmol/L NA
(Figure 2A). The correlation between the different concentrations
of visfatin used for pre-incubation prior to NA contraction and the
pD2 values obtained for ACh is shown in Figure 2B.
Furthermore, we observed that the relaxation elicited by ACh in
rat microvessels was not modified by indomethacin (10 mmol/L)
but was blunted by around 60% in the presence of L-NAME
(100 mmol/L) (Figure 2C). Indeed, only the L-NAME-sensitive
component of the ACh-induced response was affected by visfatin
(100 ng/mL) (Figure 2C).
On the other hand, the pre-incubation of rat microvessels with
visfatin (50 and 100 ng/mL) prior to NA contraction did not
interfere with the relaxations elicited by the endothelium-
independent vasodilator SNP (1 nmol/L to 3 mmol/L) (Figure 2D).
NADPH oxidase activity mediates the impaired
endothelium-dependent vasodilation induced by visfatin
in rat microvessels
To gain insight into the mechanisms mediating the impaired
endothelium-dependent vasodilation induced by visfatin in rat
microvessels, we next explored the impact of the adipokine on
NADPH oxidase activation, considered as a major mechanism
involved in endothelial dysfunction [12,13].
As a first approach to address this question, we stimulated
cultured HUVEC with increasing concentrations of visfatin (10 to
100 ng/mL) and determined the formation of superoxide anions
through NADPH oxidase activity. Thus, after 20–30 min of
incubation, visfatin elicited a concentration-dependent activation
of endothelial NADPH oxidase activity, as shown in Figure 3A.
Similarly, in rat mesenteric microvascular preparations, visfatin,
used at a concentration of 50 ng/mL, triggered a marked
activation of NADPH oxidase (757,17613,55% of basal activa-
tion, results from three independent experiments; P,0,05).
Indeed, the pre-incubation of rat microvessels with the NADPH
oxidase inhibitor apocynin (10 mmol/L) totally restored to control
levels the impaired relaxation to ACh (100 pmol/L to 3 mmol/L)
induced by 50 ng/mL visfatin (Figure 3B). The pre-incubation
with apocynin also restored the sensitivity of visfatin-treated
microvessels to L-NAME. Thus, the pD2 for ACh after pre-
incubation with visfatin, apocynin and L-NAME together
(7.0660.17) was equivalent to that obtained after pre-incubation
with visfatin plus L-NAME (6.8560.12) or with L-NAME alone
(6.7860.20), and significantly higher than in control microvessels
(7.6960.16; P,0.05; results from 12 segments obtained from 6
animals). In the absence of visfatin, apocynin did not modify the
relaxation induced by ACh (Figure 3B).
Figure 3. NADPH oxidase mediates the impaired vasodilation to ACh induced by visfatin in rat mesenteric microvessels. (A) Cultured
human umbilical vein endothelial cells were stimulated with increasing concentrations of visfatin (10 to 100 ng/mL) for 20–30 min and the
generation of superoxide anions by NADPH oxidase was determined lucigenin-derived chemiluminiscence. Results are expressed as mean 6 SEM
obtained from 6 experiments performed in triplicate. *P,0.05 vs control cultures without visfatin. (B) Rat microvessels were pre-incubated with
visfatin (50 ng/mL) and/or apocynin (10 mmol/L), contracted with 1 mmol/L NA and then exposed to cumulative concentrations of ACh (100 pmol/L
to 3 mmol/L). Results are expressed as mean 6 SEM of 35 segments from 5 animals. *P,0.05 vs control curve; {P,0.05 vs visfatin.
doi:10.1371/journal.pone.0027299.g003
Figure 4. The impaired relaxation to ACh induced by visfatin in
rat microvessels does not depend on the insulin receptor. The
microvessels were pre-incubated with visfatin (50 ng/mL) alone or
combined with either an antibody blocking the activation of the insulin
receptor (InsR Ab; 2 mg/mL) and then contracted with 1 mmol/L NA and
exposed to increasing concentrations of ACh (100 pmol/L to 3 mmol/L).
Results are expressed as mean 6 SEM of 20 segments obtained from 4
animals. *P,0.05 vs control curve.
doi:10.1371/journal.pone.0027299.g004
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Figure 5. The activation of NADPH oxidase and the impaired relaxation to ACh induced by visfatin in rat microvessels relies on
Nampt activity. (A) NADPH oxidase activity was measured in cultured human umbilical vein endothelial cells (HUVEC) stimulated for 20–30 min
with visfatin (50 ng/mL), the Nampt inhibitor APO866 (10 mmol/L) or both compounds together, as well as with the product of the Nampt reaction
NMN (10 and 100 mmol/L). Results are expressed as mean 6 SEM of 5 experiments performed in triplicate. *P,0.05 vs control cultures; {P,0.05 vs
Visfatin Impairs Endothelium-Dependent Relaxation
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Furthermore, the co-incubation with the extracellular superox-
ide anions scavenger enzyme SOD, did not prevent the impaired
relaxation to ACh elicited by visfatin (data not shown).
The activation of NADPH oxidase and the impaired
relaxation to ACh induced by visfatin in rat microvessels
relies on Nampt activity
When first described as an adipokine, visfatin was proposed to
act through binding to the insulin receptor [1]. Thus, in another
set of experiments, the rat microvessels were pre-incubated with a
commercial antibody (2 mg/mL) that binds to the a-subunit of the
insulin receptor and blocks the receptor activation [17]. Such
treatment neither prevented the impairment of ACh-dependent
vasodilation induced by visfatin (50 ng/mL) nor modified itself the
relaxation to ACh in the absence of visfatin (Figure 4).
Moreover, we explored the role of Nampt enzymatic activity on
the impaired relaxation elicited by visfatin. Thus, the pre-
incubation of cultured HUVEC with the Nampt inhibitor
APO866 (10 mmol/L) completely prevented the activation of
NADPH oxidase triggered by 50 ng/mL visfatin in both HUVEC
and mesenteric microvascular preparations (Figures 5A and 5B).
Furthermore, the stimulation of HUVEC cultures with the final
product of the Nampt reaction NMN (10 and 100 mmol/L)
resulted in a marked increase of NADPH activity (Figure 5A).
Such effect of NMN (100 mM) was not significantly modified by
APO866 (105,99614,90% of the activation achieved by NMN
alone; results from 3 independent experiments performed in
triplicate). Moreover, the effect of visfatin (50 ng/ml) on NADPH
oxidase activation was not significantly modified by co-incubation
with NMN (100 mM) (111,4868,34% of the activation achieved
by visfatin alone in HUVEC; results from 4 independent
experiments performed in triplicate).
Similarly, in reactivity experiments, APO866 (10 nmol/L to
10 mmol/L) concentration-dependently restored the impaired
microvascular relaxation to ACh (100 pmol/L to 3 mmol/L)
elicited by 50 ng/mL visfatin (Figure 5C). Figure 5D depicts the
correlation between the APO866 concentrations used and the pD2
values for ACh. In the absence of visfatin, APO866 alone did not
modify the vascular responses to ACh (data not shown). Moreover,
the pre-incubation with NMN (100 nmol/L to 1 mmol/L)
impaired in a concentration-dependent manner the vasorelaxant
response of rat microvessels to ACh (Figure 5E). The correlation
between the NMN concentrations used and the pD2 values for
ACh is shown in Figure 5F.
Visfatin impairs the endothelium-dependent vasodilation
to BK in human mesenteric microvessels through Nampt
activity
We finally assessed whether the impaired vasorelaxation
induced by visfatin in rat mesenteric arteries could also be
observed in microvessels of human origin. Thus, Figure 6 shows
that visfatin (50 ng/mL) impaired the relaxation to BK (1 nmol/L
to 3 mmol/L) in human mesenteric arteries. Such an effect was
restored by pre-incubation with the Nampt inhibitor APO866
(10 mmol/L), while APO866 itself did not modify the relaxant
responses to BK of human microvessels in the absence of visfatin
(Figure 6).
Discussion
Endothelial dysfunction, which can be defined as the loss of
balance between the multiple factors controlling reactivity,
inflammation, coagulation and cell growth at the vascular level,
is a key event tightly associated to the development of vascular
diseases, including atherosclerosis and coronary artery disease. In
the last years, several clinical studies have shown a positive
correlation between enhanced visfatin plasma levels and endothe-
lial dysfunction [5–9], while in particular clinical conditions such
as renal transplantation, plasma visfatin has been even identified as
a strong predictor of FMD both before and after transplantation
[11].
In the present study, we have demonstrated that, besides
representing a biomarker of endothelial dysfunction and vascular
damage, visfatin is also an active player that can directly impair
vascular reactivity. More specifically, visfatin reduced the
vasorelaxant responses to different endothelium-dependent vaso-
dilators, such as ACh and BK, without affecting the endothelium-
independent relaxant capacity of vascular smooth muscle.
Importantly, such a deleterious action of visfatin was observed
visfatin (B) Effect of visfatin (50 ng/mL) and APO866 (10 mmol/L), alone or in combination, on NADPH oxidase activity in rat microvascular
preparations. Results are expressed as mean 6 SEM of 8 segments obtained from 4 animals. *P,0.05 vs control cultures; {P,0.05 vs visfatin. (C) Rat
microvessels were pre-incubated with visfatin (50 ng/mL), alone or in the presence of APO866 (10 nmol/L to 10 mmol/L), subsequently contracted
with 1 mmol/L NA and then exposed to increasing concentrations of ACh (100 pmol/L to 3 mmol/L). Results are expressed as mean 6 SEM of 58
segments obtained from 11 animals. *P,0.05 vs control curve; {P,0.05 vs visfatin alone. (D) Correlation between the APO866 concentrations used
for pre-incubation and the pD2 values for ACh. (E) The vessels were pre-incubated with NMN (100 nmol/L to 1 mmol/L), contracted with 1 mmol/L NA
and then relaxed with cumulative concentrations of ACh (100 pmol/L to 3 mmol/L). Results represent the mean6 SEM of 32 segments obtained from
5 animals. *P,0.05 vs control curve. (F) Correlation between the NMN concentrations used for pre-incubation and the pD2 values for ACh.
doi:10.1371/journal.pone.0027299.g005
Figure 6. Visfatin impairs the relaxation induced by BK in
human mesenteric microvessels via Nampt activity. Human
microvessels were pre-incubated with visfatin (50 ng/mL) and/or the
Nampt inhibitor APO866 (10 mmol/mL), contracted with 35 mmol/L KCl
and then exposed to increasing concentrations of BK (1 nmol/L to
3 mmol/L). *P,0.05 vs control curve; {p,0.05 vs visfatin alone. Results
are expressed as mean6 SEM of 30 segments obtained from 4 subjects.
doi:10.1371/journal.pone.0027299.g006
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not only in rat microvessels but also in isolated microvessels of
human origin. Indeed, visfatin did impair microvascular relaxation
from a concentration of 25–50 ng/mL, which can be found in the
circulation of patients suffering from obesity, type 2 diabetes or
chronic kidney disease, whereas their matched healthy controls
exhibit lower levels [11,18,19].
To date, the scarce reports available on the regulation of the
vascular tone by visfatin have been rather contradictory. Indeed,
Yamawaki et al. [20] reported that the addition of visfatin to an
organ bath resulted in a modest although significant endothelium-
dependent relaxation in both rat aortas and mesenteric arteries
pre-contracted with NA. The vasorelaxant action of visfatin
appeared to be independent of the insulin receptor, and was
explained by the activation of endothelial nitric oxide synthase
(eNOS) through phosphorylation at serine 1177 via Akt and de-
phosphorylation at threonine 475 [20]. In another in vitro study,
Lovren et al. [21] further reported the stimulation of both eNOS
activity and expression by visfatin, leading to enhanced production
of nitric oxide and cyclic GMP formation in cultured human
umbilical vein and coronary endothelial cells. However, these
effects, which were observed after longer stimulation times with
visfatin, were not considered beneficial by the authors, but were
rather linked to endothelial cell proliferation and angiogenesis
considered as two deleterious pro-atherosclerotic events [21].
More recently, a study by Xia et al. [22] has shown that visfatin
inhibits the vasorelaxant response to BK in bovine coronary
arteries, which is in line with the results presented herein.
Regarding the ability of visfatin to modify the vascular
contractility, Yamawaki et al. [20] have reported that visfatin
can slightly reduce the vasoconstrictor action of NA in rat aortas.
Nevertheless, we could not observe any influence of the
adipocytokine on NA-induced vasoconstriction in rat mesenteric
arteries.
To gain insight into the mechanisms mediating the impaired
vasodilation elicited by visfatin, we explored the potential role of
NADPH oxidase. This superoxide anions-generating enzymatic
complex has been tightly linked to the development of endothelial
dysfunction [12,13]. Indeed, visfatin rapidly stimulated NADPH
oxidase activity in cultured human endothelial cells. Such an acute
effect cannot be explained by de novo synthesis of NADPH oxidase
components, but rather relies on enhanced enzymatic functionality.
In this context, it has been recently shown in bovine coronary artery
endothelial cells that visfatin favors gp91 subunit aggregation in
membrane rafts clusters as well as the translocation of the p47
subunit to these clusters, therefore increasing NADPH activity and
superoxide anion release, as determined by electronic spin resonance
[22]. Interestingly, visfatin also facilitates NADPH oxidase activation
in immune cells, such as human polymorphonuclear neutrophils, by
promoting the translocation of p47 and p40 subunits to the cell
membrane [23]. In rat mesenteric microvessels, we found NADPH
oxidase activity to be a crucial mediator of the impaired vasodilation
induced by visfatin through the intracellular release of superoxide
anions, since apocynin, but not SOD, prevented such impairment.
Although NADPH oxidase can favor endothelial dysfunction
through different mechanisms, the quenching and inactivation of
endothelial NO by an excess production of reactive oxygen species is
a major mechanism linking NADPH oxidase activation and
impaired vasodilation [12,13]. Indeed, in rat mesenteric microves-
sels, visfatin blunted the vasorelaxant responses sensitive to L-
NAME, i.e., dependent on the endothelial release of NO, without
affecting a remaining indomethacin- and L-NAME-independent
relaxant component, which might be attributed to endothelium-
derived hyperpolarizing factor [15]. Furthermore, the fact that rat
microvessels pre-incubated with visfatin and apocynin exhibited
restored sensitivity to L-NAME further supports a diminished NO
bioavailability upon NADPH oxidase activation by visfatin.
As stated before, visfatin was initially claimed to act as insulin
mimetic [1]. However, the present study discards a role for insulin
receptors in mediating the impaired endothelium-dependent
relaxation elicited by visfatin. Instead, Nampt activity arises as
the central mechanism mediating the deleterious action of visfatin
on microvascular reactivity; thus, the effects of visfatin on NADPH
oxidase activation and endothelial-dependent vasodilation were
mimicked by NMN, the product of Nampt activity, while it was
prevented by the Nampt inhibitor APO866. The fact that visfatin
and NMN did not exhibit additive effects on NADPH oxidase
activation further suggests that both compounds share a common
signaling pathway. In line with these observations, Nampt activity
has been shown to mediate several biological actions of visfatin,
including vascular smooth muscle cell proliferation and inflam-
mation, the production of matrix metalloproteinases by macro-
phages, or the release of insulin by b-pancreatic cells [24–27].
To date, several reports have demonstrated that visfatin can
directly induce a series of vascular events closely related to
endothelial dysfunction and vascular damage, such as endothelial
cell and vascular smooth muscle cell inflammation [25,28,29],
vascular smooth muscle proliferation [24], or matrix metallopro-
teinases activation [27,30]. In the present study, we provide an
additional vasoactive mechanism by which visfatin might further
contribute to endothelial dysfunction and to the development of
vascular diseases, particularly atherosclerosis. In this context,
enhanced circulating visfatin levels have been recently identified as
a novel marker of carotid atherosclerosis in type 2 diabetes mellitus
patients [31], while a positive association has also been found
between plasma visfatin concentrations and CAD, particularly
acute coronary syndromes [32]. It is worth noting that a positive
correlation also exists between coronary atherosclerosis and the
expression of visfatin in the periaortic and pericoronary fat [33],
highlighting that not only circulating but also perivascular visfatin
might contribute to the onset of endothelial dysfunction and the
development of atherosclerotic lesions.
In conclusion, visfatin impairs microvascular endothelium-
dependent relaxation through a mechanism involving NADPH
oxidase stimulation and relying on Nampt enzymatic activity.
Visfatin therefore arises as both a new direct player and a potential
therapeutical target in the context of endothelial dysfunction.
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